These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 20424448)
1. Animal models related to congenital heart disease and clinical research in pulmonary hypertension. Loukanov T; Geiger R; Agrawal R Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448 [TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628 [TBL] [Abstract][Full Text] [Related]
5. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034 [TBL] [Abstract][Full Text] [Related]
6. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Lian TY; Jiang X; Jing ZC Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514 [TBL] [Abstract][Full Text] [Related]
7. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Mielniczuk LM; Swiston JR; Mehta S Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043 [TBL] [Abstract][Full Text] [Related]
8. [The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension]. Cui N; Yang YH; Xie WM; Ma ZH; Luo L; Wang C Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):522-6. PubMed ID: 19954007 [TBL] [Abstract][Full Text] [Related]
9. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341 [TBL] [Abstract][Full Text] [Related]
10. Riociguat: a novel new drug for treatment of pulmonary hypertension. Makowski CT; Rissmiller RW; Bullington WM Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143 [TBL] [Abstract][Full Text] [Related]
11. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Belik J Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340 [TBL] [Abstract][Full Text] [Related]
12. [Dana Point: what is new in the treatment of pulmonary hypertension?]. Hoeper MM; Ghofrani HA; Grimminger F; Rosenkranz S Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S191-5. PubMed ID: 18814094 [TBL] [Abstract][Full Text] [Related]
13. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Ghofrani HA; Grimminger F Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121 [TBL] [Abstract][Full Text] [Related]
15. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Gorenflo M; Gu H; Xu Z Cardiology; 2010; 116(1):10-7. PubMed ID: 20424447 [TBL] [Abstract][Full Text] [Related]
16. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension. DeSouza SA; Preston IR Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801 [TBL] [Abstract][Full Text] [Related]
17. Riociguat for the treatment of pulmonary hypertension. Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889 [TBL] [Abstract][Full Text] [Related]